Total Payments
$5,561
2024 Payments
$413.72
Companies
30
Transactions
87
Medicare Patients
8,517
Medicare Billing
$3.1M
Payment Breakdown by Category
Other$3,225 (58.0%)
Food & Beverage$2,166 (38.9%)
Education$169.98 (3.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,375 | 3 | 42.7% |
| Food and Beverage | $2,166 | 76 | 38.9% |
| Honoraria | $850.00 | 1 | 15.3% |
| Education | $169.98 | 7 | 3.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $2,462 | 5 | $0 (2017) |
| PFIZER INC. | $1,069 | 13 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $321.43 | 11 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $247.95 | 9 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $148.31 | 2 | $0 (2018) |
| Amgen Inc. | $134.66 | 4 | $0 (2017) |
| Janssen Pharmaceuticals, Inc | $127.90 | 2 | $0 (2021) |
| Pharmacyclics LLC, An AbbVie Company | $124.99 | 1 | $0 (2017) |
| Kite Pharma, Inc. | $115.50 | 2 | $0 (2022) |
| Incyte Corporation | $99.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $413.72 | 15 | E.R. Squibb & Sons, L.L.C. ($123.37) |
| 2023 | $370.84 | 19 | PFIZER INC. ($136.44) |
| 2022 | $266.45 | 11 | Novartis Pharmaceuticals Corporation ($139.65) |
| 2021 | $215.24 | 4 | Janssen Pharmaceuticals, Inc ($102.62) |
| 2020 | $961.64 | 8 | PFIZER INC. ($853.95) |
| 2019 | $38.79 | 2 | E.R. Squibb & Sons, L.L.C. ($34.16) |
| 2018 | $287.10 | 6 | Takeda Pharmaceuticals U.S.A., Inc. ($148.31) |
| 2017 | $3,007 | 22 | AstraZeneca Pharmaceuticals LP ($2,462) |
All Payment Transactions
87 individual payment records from CMS Open Payments — Page 3 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/11/2020 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: Oncology | ||||||
| 02/25/2020 | Exelixis Inc. | Cabometyx (Drug) | Education | In-kind items and services | $22.00 | General |
| Category: Oncology | ||||||
| 02/25/2020 | Exelixis Inc. | Cabometyx (Drug) | Education | In-kind items and services | $17.66 | General |
| Category: Oncology | ||||||
| 02/13/2020 | PFIZER INC. | INLYTA (Drug), BAVENCIO, LORBRENA | Food and Beverage | In-kind items and services | $3.95 | General |
| Category: ONCOLOGY | ||||||
| 02/12/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: ONCOLOGY | ||||||
| 02/05/2020 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $11.14 | General |
| Category: Oncology | ||||||
| 01/28/2020 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $25.28 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/18/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $4.63 | General |
| Category: ONCOLOGY | ||||||
| 03/26/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $34.16 | General |
| Category: Oncology | ||||||
| 10/30/2018 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: ONC | ||||||
| 10/17/2018 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $23.31 | General |
| Category: Oncology | ||||||
| 10/11/2018 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 09/20/2018 | Janssen Biotech, Inc. | Erleada (Drug), ZYTIGA | Food and Beverage | In-kind items and services | $14.45 | General |
| Category: Oncology | ||||||
| 06/07/2018 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $12.64 | General |
| 04/10/2018 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $11.70 | General |
| Category: Oncology | ||||||
| 11/14/2017 | Incyte Corporation | — | Education | Cash or cash equivalent | $99.00 | General |
| 11/08/2017 | AstraZeneca Pharmaceuticals LP | — | Education | In-kind items and services | $5.00 | General |
| 08/24/2017 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $11.45 | General |
| Category: Oncology | ||||||
| 08/17/2017 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Oncology | ||||||
| 05/10/2017 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Oncology | ||||||
| 05/03/2017 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $82.10 | General |
| Category: Oncology | ||||||
| 05/02/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $22.53 | General |
| Category: Oncology | ||||||
| 04/20/2017 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $225.00 | General |
| Category: Oncology | ||||||
| 04/11/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.34 | General |
| Category: Oncology | ||||||
| 04/07/2017 | Amgen Inc. | Kyprolis (Biological) | Education | In-kind items and services | $5.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 36 | 1,732 | 34,646 | $2.5M | $622,441 |
| 2022 | 46 | 2,060 | 53,044 | $3.6M | $823,847 |
| 2021 | 40 | 2,107 | 39,668 | $2.9M | $665,740 |
| 2020 | 47 | 2,618 | 52,638 | $4.2M | $987,255 |
Total Patients
8,517
Total Services
179,996
Medicare Billing
$3.1M
Procedure Codes
169
All Medicare Procedures & Services
169 procedure records from CMS Medicare Utilization — Page 2 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 23 | 550 | $62,700 | $440.30 | 0.7% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 11 | 23 | $2,622 | $422.18 | 16.1% |
| 83540 | Iron level | Office | 2023 | 44 | 60 | $1,620 | $380.40 | 23.5% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2023 | 21 | 53 | $1,802 | $336.02 | 18.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 11 | $1,650 | $301.14 | 18.3% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 34 | 48 | $1,488 | $284.16 | 19.1% |
| 85007 | Microscopic examination for white blood cells with manual cell count | Office | 2023 | 21 | 53 | $1,166 | $197.16 | 16.9% |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | Office | 2023 | 11 | 460 | $11,040 | $136.00 | 1.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 33 | 1,332 | $1,332 | $130.30 | 9.8% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 12 | 17 | $476.00 | $52.87 | 11.1% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 17 | 44 | $308.00 | $34.87 | 11.3% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2022 | 19 | 14,200 | $1.9M | $587,678 | 31.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 133 | 480 | $176,640 | $44,305 | 25.1% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2022 | 16 | 13,650 | $273,000 | $33,783 | 12.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 63 | 273 | $193,011 | $27,899 | 14.5% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 41 | 154 | $24,640 | $24,555 | 99.7% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2022 | 17 | 19 | $91,238 | $21,642 | 23.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 195 | 308 | $77,000 | $18,246 | 23.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 13 | 67 | $246,225 | $9,082 | 3.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 266 | 971 | $34,956 | $7,450 | 21.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 51 | 321 | $50,397 | $7,372 | 14.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 232 | 635 | $40,640 | $6,620 | 16.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 33 | 111 | $38,184 | $5,637 | 14.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 40 | 40 | $22,600 | $4,630 | 20.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 41 | 41 | $15,252 | $3,175 | 20.8% |
About Dr. Daniel Farray-Berges, M.D
Dr. Daniel Farray-Berges, M.D is a Medical Oncology healthcare provider based in Weslaco, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1639116288.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Farray-Berges, M.D has received a total of $5,561 in payments from pharmaceutical and medical device companies, with $413.72 received in 2024. These payments were reported across 87 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2,375).
As a Medicare-enrolled provider, Farray-Berges has provided services to 8,517 Medicare beneficiaries, totaling 179,996 services with total Medicare billing of $3.1M. Data is available for 4 years (2020–2023), covering 169 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Weslaco, TX
- Active Since 06/01/2006
- Last Updated 10/22/2008
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1639116288
Products in Payments
- TAGRISSO (Drug) $2,457
- OPDIVO (Biological) $185.42
- PROMACTA (Drug) $158.96
- NINLARO (Drug) $148.31
- Kyprolis (Biological) $134.66
- XARELTO (Drug) $127.90
- Imbruvica (Drug) $124.99
- Yescarta (Drug) $100.00
- XTANDI (Drug) $88.10
- TALZENNA (Drug) $85.98
- INLYTA (Drug) $81.12
- Lenvima (Drug) $67.94
- ADCETRIS (Biological) $57.81
- IBRANCE (Drug) $51.83
- DARZALEX (Biological) $47.34
- REBLOZYL (Biological) $39.76
- Cabometyx (Drug) $39.66
- TASIGNA (Drug) $29.34
- SCEMBLIX (Drug) $27.98
- OSTEOCOOL RF ABLATION SYSTEM (Device) $23.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.